Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Ledermann

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 6, 2021
The systemic treatment of recurrent ovarian cancer revisitedT Baert, A Ferrero, J Sehouli, et al.
Lancet (London, England)|June 27, 2003
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trialM K B Parmar, J A Ledermann, N Colombo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2012
Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)T Ruers, C Punt, F Van Coevorden, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 30, 2014
A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†I A McNeish, J A Ledermann, L Webber, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 8, 2017
Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network settingI Ray-Coquard, AnnaLisa Trama, M J Seckl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1996
Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research CouncilM T Seymour, M L Slevin, D J Kerr, et al.
ESMO Open|December 17, 2021
Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II studyJ A Ledermann, B Zurawski, F Raspagliesi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 2, 2020
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancerR E Miller, A Leary, C L Scott, et al.
ESMO Open|February 20, 2021
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trialJ A Ledermann, A C Embleton-Thirsk, T J Perren, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2019
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 studyU A Matulonis, R Shapira-Frommer, A D Santin, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 6, 2021
The systemic treatment of recurrent ovarian cancer revisitedT Baert, A Ferrero, J Sehouli, et al.
Lancet (London, England)|June 27, 2003
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trialM K B Parmar, J A Ledermann, N Colombo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2012
Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)T Ruers, C Punt, F Van Coevorden, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 30, 2014
A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†I A McNeish, J A Ledermann, L Webber, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 8, 2017
Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network settingI Ray-Coquard, AnnaLisa Trama, M J Seckl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1996
Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research CouncilM T Seymour, M L Slevin, D J Kerr, et al.
ESMO Open|December 17, 2021
Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II studyJ A Ledermann, B Zurawski, F Raspagliesi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 2, 2020
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancerR E Miller, A Leary, C L Scott, et al.
ESMO Open|February 20, 2021
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trialJ A Ledermann, A C Embleton-Thirsk, T J Perren, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2019
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 studyU A Matulonis, R Shapira-Frommer, A D Santin, et al.
Pageof 7